WKU biology professor Noah Ashley has been awarded a three-year, $429,768 R15 grant from the National Institute of General Medical Sciences (NIGMS), one of the 27 institutes and centers of the National Institutes of Health (NIH), to continue research that investigates how stress is involved in regulating the inflammatory response to sleep loss.
“This research evaluates the mechanisms that lead to inflammation from sleep loss. One of those mechanisms involves stress,” Dr. Ashley said. “In the past year, the pandemic has caused stress in all of our lives. It’s also affected our quantity and quality of sleep. So this research is incredibly relevant today.”
Congressman Brett Guthrie announced the grant Friday afternoon. “I’m thrilled the National Institutes of Health has chosen to fund research at Western Kentucky University that could potentially be used as a foundation for treatments for people who experience inflammation due to sleep loss,” said Guthrie. “We have the best environment in the world to promote scientific research and support scientists like Dr. Ashley in their important work. I currently oversee the NIH in my senior role on the Energy and Commerce Committee, and I’m a strong believer in supporting research that can lead to innovative treatments and cures. I wish Dr. Ashley and his team good luck on this multi-year research project.”
The project’s premise relates to the worldwide increases in obesity that have led to a higher incidence of obstructive sleep apnea, which is characterized by recurring events of airway collapse during sleep, intermittent low oxygen levels and fragmented sleep.
Previous research has linked sleep fragmentation with increased inflammatory responses that could provide a link between disturbed sleep and adverse health outcomes, Dr. Ashley said.
“Chronic inflammation can have a huge impact on someone’s life by increasing the risk for development of cardiovascular disease, diabetes and cancer,” he said. “If we can understand how inflammation arises from sleep loss, then potential therapeutics could be developed to mitigate inflammation in patients who experience dysregulated sleep, like obstructive sleep apnea.”
